MIRA Pharmaceuticals, Inc.
MIRA
$0.96
-$0.01-1.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.77M | 5.02M | 5.13M | 5.20M | 4.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.49M | 7.11M | 7.87M | 8.06M | 8.02M |
| Operating Income | -10.49M | -7.11M | -7.87M | -8.06M | -8.02M |
| Income Before Tax | -10.44M | -6.86M | -7.77M | -7.92M | -7.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.44 | -6.86 | -7.77 | -7.92 | -7.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.44M | -6.86M | -7.77M | -7.92M | -7.85M |
| EBIT | -10.49M | -7.11M | -7.87M | -8.06M | -8.02M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.52 | -1.52 | -0.48 | -0.50 | -0.51 |
| Normalized Basic EPS | -0.25 | -0.26 | -0.30 | -0.31 | -0.32 |
| EPS Diluted | -1.52 | -1.52 | -0.48 | -0.50 | -0.51 |
| Normalized Diluted EPS | -0.25 | -0.26 | -0.30 | -0.31 | -0.32 |
| Average Basic Shares Outstanding | 93.73M | 69.47M | 65.26M | 63.06M | 61.19M |
| Average Diluted Shares Outstanding | 93.73M | 69.47M | 65.26M | 63.06M | 61.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |